drugset / Trial / NCT00873795

Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression

NCT00873795

Completed 41 enrolled Chimei Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

FDA has accepted atypical antipsychotics of olanzapine and aripiprazole as the adjuvant medications for refractory major depression. But there is still no trial about atypical antipsychotics combined with antidepressant of SSRI used in fresh major depressive patients. This project aims to compare the efficacy and tolerability of sertraline with or without low-dosed aripiprazole added in fresh major depression.

Timeline

Start
2007-04
Primary completion
2009-03
Completion
2009-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 2.5 mg
Background Sertraline Small molecule 50 mg